Analyst Price Target is $8.50
▲ +504.98% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Chemomab Therapeutics in the last 3 months. The average price target is $8.50, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 504.98% upside from the last price of $1.41.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Chemomab Therapeutics. This rating has held steady since January 2025, when it changed from a Strong Buy consensus rating.